SAG
TVTX icon

SageView Advisory Group’s Travere Therapeutics TVTX Stock Holding History

SageView Advisory Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,036
Closed -$77.8K – 2296
2025
Q4 		$77.8K Buy
+2,036
New +$66.2K ﹤0.01% 912

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SageView Advisory Group's TVTX Position: Q1 2026 in Review

SageView Advisory Group sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 2,036 shares — an estimated $77.8K sold.

SageView Advisory Group first reported a position in TVTX in Q4 2025 and held it in 1 quarter. The position peaked at $77.8K in Q4 2025. 261 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • SageView Advisory Group reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 2,036 Travere Therapeutics shares in Q1 2026, an estimated $77.8K.
  • SageView Advisory Group first reported a position in Travere Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Travere Therapeutics position peaked at $77.8K in Q4 2025.
  • 261 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.